Researchers Released Living Review of MDMA Therapy
A new interactive database tracks evidence on MDMA-assisted therapy for PTSD to help patients and providers.
Updated on Oct. 11, 2026 in Substance Abuse
Live Poll
Would you consider experimental therapies as a valid alternative to traditional psychiatric medications?
Researchers published a living systematic review and meta-analysis examining MDMA-assisted therapy for PTSD. The team also launched an interactive dashboard to provide ongoing updates on the treatment, which is intended to address limitations in current clinical trial data.
Why it matters
PTSD affects 6% of the general population and up to 32% of emergency responders, resulting in $23.2 billion in annual costs. This initiative aims to synthesize complex evidence to support better treatment decisions beyond current FDA-approved options like paroxetine and sertraline.
This living systematic review incorporates data from 13 active phase 2 or 3 trials to evaluate MDMA-assisted therapy. The project aims to address the limitations of existing research, though conclusive comparative outcomes remain under investigation.
The players
FDA
The federal agency responsible for approving safe and effective treatments for psychiatric conditions including PTSD.
The details
The MDMA-assisted therapy protocol involves preparatory sessions followed by dosing sessions that typically last 8 to 10 hours, concluding with integration sessions. Researchers created the SYPRES website to provide continuous access to raw data, effect sizes, and analysis code. This transparency is designed to mitigate the gaps in evidence seen with existing trauma-focused cognitive behavioral therapies, which see dropout rates between 20% and 30%.
Timeline
October 11, 2026: Researchers published the living systematic review.
Health Landscape
This review sits within the broader effort to modernize psychiatric care as current treatments like paroxetine and sertraline are the only options currently sanctioned by the FDA. The project follows the infrastructure established by the Metapsy database to track the evolution of evidence in mental health.
If you or a loved one are managing PTSD, it is worth discussing the current status of experimental treatments with a qualified psychiatrist or mental health professional. Understanding that current evidence is still evolving can help you have more informed conversations about your care options.
The takeaway
Ongoing clinical research is working to expand the toolkit for treating PTSD beyond traditional pharmaceutical options. Patients should track this research through reputable clinical dashboards and consult their physician regarding which therapies are appropriate for their specific care plan.
What happens next
The research team plans to release updates to the systematic review on at least an annual basis.
Further reading
Learn more about the latest clinical research and trends in Substance Abuse.
More information
View the ongoing findings and clinical data on the SYPRES research data and results.
Source note: This article includes information reported by Nature.
Live Poll
Would you consider experimental therapies as a valid alternative to traditional psychiatric medications?
